Unknown

Dataset Information

0

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.

ABSTRACT: Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

SUBMITTER: Kuiper RP 

PROVIDER: S-EPMC9291030 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.

Kuiper Roland P RP   Hoogeveen Patricia G PG   Bladergroen Reno R   van Dijk Freerk F   Sonneveld Edwin E   van Leeuwen Frank N FN   Boer Judith J   Sergeeva Irina I   Feitsma Harma H   den Boer Monique L ML   van der Velden Vincent H J VHJ  

British journal of haematology 20210801 5

Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic dele  ...[more]

Similar Datasets

Unknown Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).
| S-EPMC3518178 | biostudies-literature
Unknown Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia.
| S-EPMC4693965 | biostudies-literature
Unknown Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia.
| S-EPMC6838385 | biostudies-literature
Unknown Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year.
| S-EPMC10605425 | biostudies-literature
Transcriptomics New markers for minimal residual disease detection in acute lymphoblastic leukemia
2011-04-20 | GSE28497 | GEO
Unknown New markers for minimal residual disease detection in acute lymphoblastic leukemia.
| S-EPMC3122946 | biostudies-literature
Unknown Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.
| S-EPMC5981136 | biostudies-literature
Transcriptomics Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia
2013-11-05 | GSE39816 | GEO
Unknown Minimal residual disease in acute myeloid leukaemia.
| S-EPMC4163748 | biostudies-literature
Unknown Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
| S-EPMC3537310 | biostudies-literature